CA-RUBICON-CARBON
9.7.2024 15:01:29 CEST | Business Wire | Press release
Rubicon Carbon, a carbon credit management firm, today announced a new partnership with Formula E Champion and ABT CUPRA driver Lucas di Grassi to purchase carbon credits using the company’s platform. Di Grassi is the first Formula E driver to offset his carbon footprint by personally investing in carbon credits.
Di Grassi built his own Rubicon Carbon Tonne (RCT), a diversified and actively managed portfolio of carbon credits that includes carbon removal, nature-based avoidance, and industrial avoidance projects. Through RCTs, buyers reduce risk and increase optionality and price certainty.
"We are excited to support Lucas and Formula E, who share our values in building a low-carbon future," said Tom Montag, CEO of Rubicon Carbon. "This partnership perfectly aligns with our mission to innovate and lead in the fight against climate change, and we look forward to helping Lucas on his path to decarbonizing the mobility and racing industries.”
To celebrate the partnership, di Grassi’s car and helmet proudly displayed Rubicon Carbon logos at last month’s Hankook Portland E-Prix in Portland, Oregon. The collaboration between Rubicon Carbon and di Grassi exemplifies the potential of sports partnerships to drive positive environmental change.
As an activist in mobility technology and the first Formula E driver to publicly sever ties with industries that do not prioritize sustainability, di Grassi has set a precedent for how to champion environmental responsibility as a professional athlete.
Speaking on the partnership, di Grassi noted, “I am proud to be the first driver to offset all the carbon I have emitted from traveling around the world since my first Formula E race in Beijing. Working with (Rubicon Carbon CEO) Tom Montag and his entire team is the perfect partnership for me, as Rubicon Carbon is the most qualified and credible carbon credit management firm in the world. In line with the values and objectives of Formula E, I drive an electric car and have adapted my lifestyle. But still, credible carbon avoidance and removal is the only way to do the sport we love and be responsible for our environment at the same time. I would be delighted if many other athletes, not only in Formula E, would consider the same path.”
This partnership follows Rubicon’s recent investments in carbon projects across the globe, including a large-scale ecosystem restoration project in Panama in partnership with Ponterra, Microsoft, and Carbon Streaming, a 250K+ acres restoration project in South Africa led by Imperative, and a collaboration with YvY Capital to scale up carbon investments in Brazil.
For more information on Rubicon Carbon, visit the website or follow on LinkedIn.
About Lucas di Grassi:
Lucas di Grassi is a founding member of Formula E, has competed in every race up until now and is the most successful driver on the grid in terms of podium positions. He was winner of the first ever race in Beijing 2014, Champion in the 2016/2017 and teams' Champion in 2017/2018. In addition to his role as an ABT CUPRA driver, Lucas di Grassi is an entrepreneur for innovation, sustainability and electric mobility. As co-founder of Zero Summit he is organizing technology and business panels for a zero-carbon future in many countries around the world. Since 2018, Lucas di Grassi is an official United Nations Ambassador for Clean Air. Lucas di Grassi lives in Monaco together with his wife Bianca, his son Leonardo and his daughter Beatriz.
About Formula E:
As the world’s first all-electric FIA World Championship and the only sport certified net zero carbon since inception, the ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation. The Formula E network of teams, manufacturers, partners, broadcasters, and host cities are united by a passion for the sport and belief in its potential to accelerate sustainable human progress and create a better future for people and planet.
About Rubicon Carbon:
Rubicon Carbon is a carbon credit management firm that partners with the world’s largest enterprises to help them achieve their sustainability goals while driving global decarbonization. Backed by TPG Rise Climate and led by top executives from across finance, technology, and climate science, Rubicon Carbon delivers innovative carbon credit solutions to global businesses while unlocking decarbonization projects at scale, all backed by rigorous in-house scientific diligence. For more information, visit www.rubiconcarbon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709047754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
